The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Brain-Derived Neurotrophic Factor in Patients With Remitted Depression

To the Editor: We read with interest the article by Alexander Neumeister, M.D., and colleagues (1). The neurobiology of brain-derived neurotrophic factor (BDNF) is complex and influenced by a number of different hormonal systems, including the hypothalamic-pituitary-adrenal (HPA) axis, which is known to be dysfunctional in patients with severe mood disorders. Stress-responsive corticosteroids, which are the end products of the HPA axis, have been shown to have important effects on the expression of BDNF in preclinical studies (2). We have also recently shown an interaction between cortisol and serum levels of BDNF in patients with bipolar depression and schizophrenia (3). Furthermore, tryptophan depletion has been shown to lower cortisol levels in patients with mood disorders (4) as well as in healthy comparison subjects (5). Of interest, sham tryptophan depletion has also been reported to cause a significant decrease of plasma cortisol (4). Changes in cortisol levels may, therefore, account for the increases in BDNF following sham depletion observed by Dr. Neumeister and colleagues.

The data presented by Dr. Neumeister et al. may indeed suggest an intimate link between the serotonergic and neurotrophic systems, but in the absence of any data regarding HPA axis function in these patients (and healthy subjects), it remains a possibility that the observed changes of expression of BDNF are secondary to differences in cortisol production. We advocate that further studies of BDNF in mood disorders also investigate HPA axis function.

References

1. Neumeister A, Yuan P, Young TA, Bonne O, Luckenbaugh DA, Charney DS, Manji H: Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry 2005; 162:805–807LinkGoogle Scholar

2. Smith MA, Makino S, Kvetnansky R, Post RM: Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15:1768–1777Crossref, MedlineGoogle Scholar

3. Mackin P, Gallagher P, Watson S, Ferrier I, Young AH: Changes in brain-derived neurotrophic factor (BDNF) following treatment with mifepristone (RU486) in bipolar disorder and schizophrenia. Biol Psychiatry 2005; 57:132S-133SGoogle Scholar

4. Johnson L, El-Khoury A, Aberg-Wistedt A, Stain-Malmgren R, Mathe AA: Tryptophan depletion in lithium-stabilized patients with affective disorder. Int J Neuropsychopharmacol 2001; 4:329–336Crossref, MedlineGoogle Scholar

5. Vielhaber K, Riemann D, Feige B, Kuelz A, Kirschbaum C, Voderholzer U: Impact of experimentally induced serotonin deficiency by tryptophan depletion on saliva cortisol concentrations. Pharmacopsychiatry 2005; 38:87–94Crossref, MedlineGoogle Scholar